PDF(Pubmed)
Abstract：
Immune checkpoint inhibitor (ICI) therapies have broadened the armamentarium for metastatic renal cell carcinoma (mRCC). As the ICI therapy spreads in the clinical settings, immune-related adverse events are more of a concern for clinicians. The present study reports three cases of mRCC treated with pembrolizumab plus axitinib and diagnosed hypopituitarism based on clinical symptoms and hormonal profile. Acute methylprednisolone infusion therapy was necessary in one case because of severe adrenal hypofunction; however, the clinical symptoms of the other two cases were controlled with oral corticosteroid therapy. To the best of our knowledge, there is no report of pembrolizumab plus axitinib related hypopituitarism in the treatment of mRCC. The present cases suggests that hypopituitarism after pembrolizumab plus axitinib treatment for mRCC can be handled with steroid therapy even after the development of hypopituitarism.
摘要：
免疫检查点抑制剂（ICI）疗法已扩大了转移性肾细胞癌（mRCC）的范围。随着ICI疗法在临床环境中的传播，免疫相关不良事件更多是临床医生关注的问题.本研究报告了3例mRCC用帕博利珠单抗联合阿西替尼治疗，并根据临床症状和激素谱诊断为垂体功能减退。急性甲基强的松龙输注治疗是必要的在一个病例，因为严重的肾上腺功能减退;然而，另外2例患者的临床症状均通过口服糖皮质激素治疗得到控制。据我们所知,没有帕姆单抗联合阿西替尼治疗mRCC相关垂体功能减退的报道.目前的病例表明，即使在垂体功能减退发展后，pembrolizumab加axitinib治疗mRCC的垂体功能减退也可以用类固醇治疗。
